Wells Fargo assumed coverage of Integra LifeSciences (IART) with an Equal Weight rating and $12 price target The firm is maintaining the current rating, price target and estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target lowered to $9 from $11 at Citi
- Integra’s MicroMatrix Flex Study Reaches Completion, Setting Up Next Steps for IART Investors
- Integra Lifesciences Charts Cautious Path After Earnings
- Integra LifeSciences price target lowered to $11 from $13 at JPMorgan
- Integra LifeSciences price target lowered to $12 from $13 at Wells Fargo